Select a medication above to begin.
Mavenclad
cladribine
Black Box Warnings .
Malignancies
may incr. malignancy risk; contraindicated in pts w/ current malignancy; weigh tx benefit vs. risk in pts w/ prior malignancy or incr. malignancy risk; follow standard cancer screening guidelines in pts receiving tx
Teratogenicity Risk
contraindicated in pregnancy and in females and males of reproductive potential w/o effective contraception due to fetal harm potential; malformations and embryolethality occurred in animals; exclude pregnancy prior to tx in females of reproductive potential; advise females and males of reproductive potential to use effective contraception during tx and x6mo after last dose in each tx course; D/C tx if pt becomes pregnant
Adult Dosing .
Dosage forms: TAB: 10 mg
Special Note
- [dosing clarification]
- Info: for pts w/ relapsing forms of multiple sclerosis, incl. relapsing-remitting dz and active secondary progressive dz; not recommended for pts w/ clinically isolated syndrome; total dose divided into 2 tx courses; each tx course divided into 2 cycles; if lymphocytes <200 hold tx and give anti-herpes prophylaxis; after 2 tx courses completed do not give additional tx w/in 2y
multiple sclerosis, relapsing forms
- [40-49.9 kg]
- Dose: 40 mg/cycle PO divided qd x4 consecutive days, then 23-27 days later, give 40 mg/cycle PO divided qd x4 consecutive days; Max: 20 mg/day; Info: repeat for 2nd tx course, starting >43wk after 1st tx course completed
- [50-59.9 kg]
- Dose: 50 mg/cycle PO divided qd x4-5 consecutive days, then 23-27 days later, give 50 mg/cycle PO divided qd x4-5 consecutive days; Max: 20 mg/day; Info: repeat for 2nd tx course, starting >43wk after 1st tx course completed
- [60-69.9 kg]
- Dose: 60 mg/cycle PO divided qd x4-5 consecutive days, then 23-27 days later, give 60 mg/cycle PO divided qd x4-5 consecutive days; Max: 20 mg/day; Info: repeat for 2nd tx course, starting >43wk after 1st tx course completed
- [70-79.9 kg]
- Dose: 70 mg/cycle PO divided qd x4-5 consecutive days, then 23-27 days later, give 70 mg/cycle PO divided qd x4-5 consecutive days; Max: 20 mg/day; Info: repeat for 2nd tx course, starting >43wk after 1st tx course completed
- [80-89.9 kg]
- Dose: 80 mg/cycle PO divided qd x4-5 consecutive days, then 23-27 days later, give 70 mg/cycle PO divided qd x4-5 consecutive days; Max: 20 mg/day; Info: repeat for 2nd tx course, starting >43wk after 1st tx course completed
- [90-99.9 kg]
- Dose: 90 mg/cycle PO divided qd x5 consecutive days, then 23-27 days later, give 80 mg/cycle PO divided qd x4-5 consecutive days; Max: 20 mg/day; Info: repeat for 2nd tx course, starting >43wk after 1st tx course completed
- [100-109.9 kg]
- Dose: 100 mg/cycle PO divided qd x5 consecutive days, then 23-27 days later, give 90 mg/cycle PO divided qd x5 consecutive days; Max: 20 mg/day; Info: repeat for 2nd tx course, starting >43wk after 1st tx course completed
- [>110 kg]
- Dose: 100 mg/cycle PO divided qd x5 consecutive days, then 23-27 days later, give 100 mg/cycle PO divided qd x5 consecutive days; Max: 20 mg/day; Info: repeat for 2nd tx course, starting >43wk after 1st tx course completed
renal dosing
- [see below]
- CrCl <60: avoid use
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class B or C: avoid use
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.